Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Transplant Cell Ther. 2023 Dec;29(12):757-762. doi: 10.1016/j.jtct.2023.08.031. Epub 2023 Sep 4. Transplant Cell Ther. 2023. PMID: 37673125
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Blood Cancer J. 2023 May 3;13(1):68. doi: 10.1038/s41408-023-00842-6. Blood Cancer J. 2023. PMID: 37137874 Free PMC article.
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Al-Juhaishi T, et al. Among authors: milton dr. Bone Marrow Transplant. 2023 Sep;58(9):1000-1007. doi: 10.1038/s41409-023-02006-3. Epub 2023 May 18. Bone Marrow Transplant. 2023. PMID: 37198234
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Br J Haematol. 2023 Aug;202(4):866-873. doi: 10.1111/bjh.18944. Epub 2023 Jun 27. Br J Haematol. 2023. PMID: 37376789
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Yalniz FF, et al. Among authors: milton dr. Transplant Cell Ther. 2024 Feb;30(2):205.e1-205.e12. doi: 10.1016/j.jtct.2023.06.015. Epub 2023 Jul 10. Transplant Cell Ther. 2024. PMID: 37437764
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Am J Hematol. 2023 Oct;98(10):1571-1578. doi: 10.1002/ajh.27029. Epub 2023 Jul 17. Am J Hematol. 2023. PMID: 37461327
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Blood Cancer J. 2024 Jan 10;14(1):4. doi: 10.1038/s41408-023-00973-w. Blood Cancer J. 2024. PMID: 38199987 Free PMC article.
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.
Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Malek AE, et al. Among authors: milton dr. Bone Marrow Transplant. 2024 May;59(5):699-704. doi: 10.1038/s41409-024-02238-x. Epub 2024 Feb 14. Bone Marrow Transplant. 2024. PMID: 38355908 No abstract available.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Among authors: milton dr. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
124 results